Literature DB >> 15962370

Effects of Changtai granules, a traditional compound Chinese medicine, on chronic trinitrobenzene sulfonic acid-induced colitis in rats.

Yong-Bing Cao1, Jun-Dong Zhang, Ya-Ying Diao, Lan Yan, De-Jun Wang, Xin-Ming Jia, Ping-Hui Gao, Ming-He Cheng, Zheng Xu, Yan Wang, Yuan-Ying Jiang.   

Abstract

AIM: To study the effects of Changtai granules (CTG), a traditional compound Chinese medicine, on chronic trinitrobenzene sulfonic acid-induced colitis in rats.
METHODS: Healthy adult Sprague-Dawley (SD) rats of both sexes, weighing 250-300 g, were employed in the present study. The rat colitis models were induced by 2,4,6-trinitrobenzene sulfonic acid (TNBS) enemas at a concentration of 100 mg/kg in 50% ethanol. The experimental animals were randomly divided into dexamethasone (DX) treatment, CTG treatment, and model control groups, which were intracolicly treated daily with DX (0.2 mg/kg), CTG at doses of 2.9, 5.7 and 11.4 g crude drug/kg, and the equal amount of saline respectively from 6 h following induction of the colitis in rats inflicted with TNBS to the end of study. A normal control group of rats treated without TNBS but saline enema was also included in the study. After 3 wk of treatment, the animals were assessed for colonal inflammatory and ulcerative responses with respect to mortality, frequency of diarrhea, histology and myeloperoxidase activity (MPO).
RESULTS: The therapeutic effect of CTG on ulcerative colitis (UC) was better than DX. CTG effectively inhibited the activity of granulocytes, macrophages and monocytes in a dose-dependent manner. Also it reduced MPO and formation of inflammation in colonic mucosal tissue. Furthermore, administration of CTG significantly prevented body mass loss and death, and decreased frequency of diarrhea in UC rats, when compared with the model control group rats.
CONCLUSION: CTG would prove to be an ideal drug for chronic UC, and is warranted to be studied further.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15962370      PMCID: PMC4315956          DOI: 10.3748/wjg.v11.i23.3539

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  28 in total

Review 1.  Inflammatory bowel disease.

Authors:  Daniel K Podolsky
Journal:  N Engl J Med       Date:  2002-08-08       Impact factor: 91.245

2.  Bone mineral density in patients with inflammatory bowel disease: a population-based prospective two-year follow-up study.

Authors:  J Jahnsen; J A Falch; P Mowinckel; E Aadland
Journal:  Scand J Gastroenterol       Date:  2004-02       Impact factor: 2.423

3.  Screening and surveillance colonoscopy in chronic Crohn's colitis.

Authors:  S Friedman; P H Rubin; C Bodian; E Goldstein; N Harpaz; D H Present
Journal:  Gastroenterology       Date:  2001-03       Impact factor: 22.682

Review 4.  Etiology of the inflammatory bowel diseases.

Authors:  J P Hugot; H Zouali; S Lesage; G Thomas
Journal:  Int J Colorectal Dis       Date:  1999-02       Impact factor: 2.571

Review 5.  Epidemiology of inflammatory bowel disease in Italy.

Authors:  M Cottone; G Martorana; R Di Mitri; C Cammà; R Caprilli
Journal:  Ital J Gastroenterol Hepatol       Date:  1999 Aug-Sep

Review 6.  The epidemiology and the pathogenesis of inflammatory bowel disease.

Authors:  K Karlinger; T Györke; E Makö; A Mester; Z Tarján
Journal:  Eur J Radiol       Date:  2000-09       Impact factor: 3.528

7.  Medical treatment: does it influence the natural course of inflammatory bowel disease?

Authors: 
Journal:  Eur J Intern Med       Date:  2000-08       Impact factor: 4.487

8.  Systemic antibodies towards mucosal bacteria in ulcerative colitis and Crohn's disease differentially activate the innate immune response.

Authors:  E Furrie; S Macfarlane; J H Cummings; G T Macfarlane
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

9.  Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models.

Authors:  J E Krawisz; P Sharon; W F Stenson
Journal:  Gastroenterology       Date:  1984-12       Impact factor: 22.682

10.  Salazosulfapyridine induced hypersensitivity syndrome associated with reactivation of humanherpes virus 6.

Authors:  Yuya Kunisaki; Hiroshi Goto; Kikuo Kitagawa; Masanori Nagano
Journal:  Intern Med       Date:  2003-02       Impact factor: 1.271

View more
  6 in total

1.  Effects of modified Sanhuang decoction () enema on serum tumor necrosis factor-α and colonic mucosa interleukin-1β, interleukin-6 levels in ulcerative colitis rats.

Authors:  Shuai Wang; Tao Zhou; Jun-Peng Zhai; Li-Hua Wang; Jing Chen
Journal:  Chin J Integr Med       Date:  2013-10-14       Impact factor: 1.978

2.  Effect of Scutellariae Radix extract on experimental dextran-sulfate sodium-induced colitis in rats.

Authors:  Ho-Lam Chung; Grace-Gar-Lee Yue; Ka-Fai To; Ya-Lun Su; Yu Huang; Wing-Hung Ko
Journal:  World J Gastroenterol       Date:  2007-11-14       Impact factor: 5.742

3.  Comparative pharmacokinetics of baicalin, wogonoside, baicalein and wogonin in plasma after oral administration of pure baicalin, radix scutellariae and scutellariae-paeoniae couple extracts in normal and ulcerative colitis rats.

Authors:  Zhen-Qiu Zhang; Wei Liua; Li Zhuang; Jing Wang; Shuai Zhang
Journal:  Iran J Pharm Res       Date:  2013       Impact factor: 1.696

Review 4.  Chinese herbal medicines in the treatment of IBD and colorectal cancer: a review.

Authors:  Maciej Sałaga; Hubert Zatorski; Marta Sobczak; Chunqiu Chen; Jakub Fichna
Journal:  Curr Treat Options Oncol       Date:  2014-09

5.  Modified Pulsatilla decoction attenuates oxazolone-induced colitis in mice through suppression of inflammation and epithelial barrier disruption.

Authors:  Xuewei Wang; Fugang Fan; Qin Cao
Journal:  Mol Med Rep       Date:  2016-06-02       Impact factor: 2.952

6.  Effects of antioxidant therapy on leukocyte myeloperoxidase and Cu/Zn-superoxide dismutase and plasma malondialdehyde levels in experimental colitis.

Authors:  Ergul Belge Kurutas; Ali Cetinkaya; Ertan Bulbuloglu; Bulent Kantarceken
Journal:  Mediators Inflamm       Date:  2005-12-14       Impact factor: 4.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.